Coleman CI, et al. - In this investigation, researchers assessed the effectiveness and safety of rivaroxaban vs warfarin in patients with stage 4 or 5 chronic kidney disease or hemodialysis in routine practice with nonvalvular atrial fibrillation. A total of 1,896 rivaroxaban users and 4,848 warfarin users were identified. According to results, rivaroxaban did not significantly lessen stroke/systemic embolism or ischemic stroke alone, but it was linked to a significant 32% decline in major bleeding risk vs warfarin. The authors concluded that rivaroxaban may be linked to significantly less major bleeding vs warfarin among nonvalvular atrial fibrillation patients with stage 4 or 5 chronic kidney disease or hemodialysis.